ROLE OF FLOW CYTOMETRY IN BLADDER CANCER

Project: Research project

Project Details

Description

This study seeks to determine the role of automated flow cytometry in
detecting transitional cell carcinoma of the bladder, in monitoring its
response to therapy, and in determining the malignant potential of
individual tumors. Efforts will be directed toward: 1. Improving sample preparation, staining and storage of bladder washing
and urine specimens. (This will include exploring protocols for fixation
and staining as well as nuclear isolation.) 2. Using paraffin-embedded pathology specimens in retrospective studies for
bladder cancer patients whose clinical outcome is known. (This will
include evaluating DNA histograms for DNA index, percent cycling cells,
statistical spread including SD and CV, and comparing the histogram
parameters to the known clinical course of the disease. In addition,
several choices of second parameters will be explored to enhance diagnostic
accuracy. These will include the use of antibodies (both polyclonal and
monoclonal) directed against oncogene products as well as monoclonal
antibodies raised against bladder cancer cells.) 3. Using freshly obtained bladder tissue for ongoing DNA flow cytometry
studies comparing the histogram parameters mentioned above to the clinical
course and pathological grade and stage of the tumor. 4. Studies of oncogene expression as determined by levels of specific
oncogene-derived products to use in (1) semiquantitative immunoperoxidase
assays and (2) the two-parameter studies described above. 5. Developing improved histogram analysis protocols and establishing an
appropriate data base for correlating the data obtained to the clinical
course of the disease in order to determine which of the parameters
studied, including clinical and pathological descriptions, are predictive
of single tumor occurrence of recurrent tumors of the same stage, or tumor
progression. Furthermore, we will attempt to decide which of these
parameters best predicts which lesions will be responsive to chemotherapy.
StatusFinished
Effective start/end date9/29/859/30/89

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

ASJC

  • Medicine(all)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.